Stifel Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $5

Over the past 3 months, 5 analysts have published their opinion on Vivid Seats (NASDAQ:SEAT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.